- Home
- UFPI vs IONS Comparison
UFPI vs IONS Comparison
Compare UFPI & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFPI
- IONS
- Stock Information
- Founded
- UFPI 1955
- IONS 1989
- Country
- UFPI United States
- IONS United States
- Employees
- UFPI N/A
- IONS N/A
- Industry
- UFPI Forest Products
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- UFPI Basic Materials
- IONS Health Care
- Exchange
- UFPI Nasdaq
- IONS Nasdaq
- Market Cap
- UFPI 6.0B
- IONS 6.8B
- IPO Year
- UFPI 1993
- IONS 1991
- Fundamental
- Price
- UFPI $92.23
- IONS $71.38
- Analyst Decision
- UFPI Buy
- IONS Strong Buy
- Analyst Count
- UFPI 2
- IONS 20
- Target Price
- UFPI $115.00
- IONS $75.55
- AVG Volume (30 Days)
- UFPI 351.0K
- IONS 2.0M
- Earning Date
- UFPI 10-29-2025
- IONS 10-29-2025
- Dividend Yield
- UFPI 1.52%
- IONS N/A
- EPS Growth
- UFPI N/A
- IONS N/A
- EPS
- UFPI 5.75
- IONS N/A
- Revenue
- UFPI $6,542,277,000.00
- IONS $944,050,000.00
- Revenue This Year
- UFPI N/A
- IONS $24.01
- Revenue Next Year
- UFPI $4.18
- IONS $4.06
- P/E Ratio
- UFPI $15.96
- IONS N/A
- Revenue Growth
- UFPI N/A
- IONS 16.05
- 52 Week Low
- UFPI $88.99
- IONS $23.95
- 52 Week High
- UFPI $141.33
- IONS $74.42
- Technical
- Relative Strength Index (RSI)
- UFPI 46.04
- IONS 70.03
- Support Level
- UFPI $89.85
- IONS $70.47
- Resistance Level
- UFPI $93.21
- IONS $74.42
- Average True Range (ATR)
- UFPI 1.81
- IONS 1.79
- MACD
- UFPI 0.48
- IONS -0.40
- Stochastic Oscillator
- UFPI 60.00
- IONS 55.13
About UFPI UFP Industries Inc.
UFP Industries Inc is a supplier of lumber to the manufactured housing industry. Today UFP Industries is a multibillion-dollar holding company with subsidiaries around the globe that serve three markets: retail, packaging and construction. Its business segments consist of UFP Retail Solutions, UFP Packaging, UFP Construction, All other and Corporate.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.